
|Slideshows|March 26, 2015
MS and Natalizumab: 3 New Findings
Author(s)Sreeram Ramagopalan, PhD
Three brand new studies shed light on use of natalizumab in relapsing-remitting multiple sclerosis.
Advertisement
Natalizumab is a highly effective therapy for relapsing-remitting multiple sclerosis. However, its efficacy in the context of other more recently available treatments needs to be assessed. Further, hampering the long-term of use of natalizumab is the association of treatment with a risk of progressive multifocal leukoencephalopathy (PML).The slides above highlight findings of 3 new studies of natalizumab.  Â
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Orexin Agonist Oveporexton for Narcolepsy Type 1
2
FDA Grants RMAT Designation to Sasineprocel for Parkinson Disease
3
FDA Accepts SL1009 Resubmission for PDCD, Sets December PDUFA Date
4
High-Dose N-Acetyl Cysteine Associated With Reduced GFAP Levels in Phase 2 Progressive MS Study
5
















